 Aztreonam-induced myelosuppression treatment Pseudomonas aeruginosa pneumonia Aztreonam synthetic monobactam antibiotic beta-lactam class drugs inhibitory activity many aerobic gram-negative bacteria gram-positive anaerobic bacteria Administration aztreonam minimal transient adverse effects case report patient experienced bone marrow suppression ten days aztreonam treatment pneumonia Pseudomonas aeruginosa untoward effect neutropenia normochromic normocytic anemia thrombocytopenia week aztreonam patient bone marrow suppression mechanism responsible myelosuppression unclear aztreonam agent temporal relationship development neutropenia administration resolution neutropenia discontinuation